Local governmental audit and accounting manual, as of March 1, 1991: a nonauthoritative practice aid

https://egrove.olemiss.edu/aicpa_guides/1211/thumbnail.jp

Local governmental audit and accounting manual, as of March 1, 1990 : a nonauthoritative practice aid

https://egrove.olemiss.edu/aicpa_guides/1210/thumbnail.jp

Local governmental audit and accounting manual, as of March 1, 1991: a nonauthoritative practice aid;Notes to the illustrative combined financial statements;

https://egrove.olemiss.edu/aicpa_guides/1005/thumbnail.jp

The Grizzly, April 15, 1983

Second Attack: Improvements Sought for Security • New Senior Fund • Seminar Planned • The A\u27s Come to Helfferich Hall • Letter to the Editor: Most Abominable Act • Faculty Promotions Approved • President\u27s Corner • Sexual Assault in Quad • Security Tips • Nuclear Freeze Concert • Ursinus Representatives at UN • Ice Cream Night at Bear\u27s Den • Final Exam Schedule • Republicans for Rock! • Escape From Ursinus • Bear Batsmen Drop Slugfest • Men\u27s Track Evens Up • Men\u27s Tennis Nets Two Wins • Girls\u27 Nets Optimistic • Men\u27s Lacrosse Victorioushttps://digitalcommons.ursinus.edu/grizzlynews/1098/thumbnail.jp

Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer

PURPOSE: Brostallicin (PNU-166196) is a cytotoxic agent that binds to the minor groove of DNA with significant antitumor activity in preclinical studies. This trial was designed to determine the maximum tolerated dose, the toxicity profile, and the pharmacokinetics of Brostallicin in cancer patients. Experimental Design: Patients were treated with escalating doses of Brostallicin ranging from 0.85 to 15 mg/m(2) administered as a 10-min i.v. infusion every 3 weeks. Blood samples for pharmacokinetic analysis were collected during the first and second course, and analyzed by liquid-chromatography with tandem-mass spectrometric detection. RESULTS: Twenty-seven evaluable patients received a total of 73 courses. Grade 4 neutropenia was the only dose-limiting toxicity at 12.5 mg/m(2), whereas grade 4 thrombocytopenia (1 patient) and grade 4 neutropenia (2 patients) were the dose-limiting toxicities at 15 mg/m(2). Other side effects, including thrombocytopenia and nausea, were generally mild. The maximum tolerated dose was defined at 10 mg/m(2). The clearance and terminal half-life of Brostallicin were dose-independent, with mean (+/-SD) values of 9.33 +/- 2.38 liters/h/m(2) and 4.69 +/- 1.88 h, respectively. There was no significant accumulation of Brostallicin with repeated administration. Significant relationships were observed between systemic exposure to Brostallicin and neutrophil counts at nadir. One partial response was observed in a patient with a gastrointestinal stromal tumor. CONCLUSION: Brostallicin was found to be well tolerated, with neutropenia being the principal toxicity. The recommended dose for additional evaluation in this schedule is 10 mg/m(2)

Gluten sensitivity enteropathy in patients with recurrent aphthous stomatitis

<p>Abstract</p> <p>Background</p> <p>Gluten sensitive enteropathy (GSE) is an autoimmune enteropathy triggered by the ingestion of gluten-containing grains in susceptible individuals. Recurrent aphthous stomatitis (RAS) may be the sole manifestation of GSE. The aim of this study was to determine the prevalence of gluten sensitivity enteropathy (GSE) in a large group of patients with RAS and assess the efficacy of gluten free diet (GFD) on the improvement of aphthous lesions in those who were diagnosed with GSE.</p> <p>Methods</p> <p>Two hundred and forty seven patients with RAS were included. The patients had at least three aphthous attacks per year. Patients were screened by IgA anti-endomysial antibody (EMA), IgA anti tissue transglutaminase (TTG) and serum IgA level. Those with a positive serology underwent endoscopic biopsies of the duodenal mucosa and patients with negative serology were excluded. The diagnosis of GSE was based on a positive serological test and abnormal duodenal histology. For patients with GSE, gluten free diet was recommended.</p> <p>Results</p> <p>Six out of 247 RAS patients had positive TTG test alone, and one had positive EMA and TTG. All 7 patients with positive serologic tests underwent duodenal biopsies. Histological findings were compatible with GSE in all of them (Marsh I in four patients, Marsh II in two patients and Marsh IIIB in one another.). The mean age of GSE patients was 27.42 ± 10.56 (range, 13 to 40) years old. They were suffering from RAS for an average duration of 4.5 years. All of the 7 GSE patients had not responded to the routine anti-aphthae medications, including topical corticosteroids, tetracycline and colchicine. Four patients who adhered to a strict gluten-free diet showed noticeable improvement in their aphthous lesions over a period of 6 months.</p> <p>Conclusion</p> <p>A significant minority (e.g. 2.83%) of RAS patients have GSE. This could be compared with the 0.9% prevalence of GSE in the general population of Iran. This study suggests that evaluation for celiac disease is appropriate in patients with RAS. Additionally, the unresponsiveness to conventional anti-aphthae treatment could be an additional risk indicator.</p

A multicenter randomized clinical trial investigating the cost-effectiveness of treatment strategies with or without antibiotics for uncomplicated acute diverticulitis (DIABOLO trial)

Background. Conservative treatment of uncomplicated or mild diverticulitis usually includes antibiotic therapy. It is, however, uncertain whether patients with acute diverticulitis indeed benefit from antibiotics. In most guidelines issued by professional organizations antibiotics are considered mandatory in the treatment of mild diverticulitis. This advice lacks evidence and is merely based on experts' opinion. Adverse effects of the use of antibiotics are well known, including allergic reactions, development of bacterial resistance to antibiotics and other side-effects. Methods. A randomized multicenter pragmatic clinical trial comparin

Reseñas

MARTIN THURNER, Gott als das offenbare Geheimnis nach Nikolaus von Kues, NICOLÁS DE CUSA, Acerca de la docta ignorancia, trad. J. M. MACHETTA / C. D’AMICO. THILO OFFERGELD, Reges pueri. Das Königtum Minderjähriger im Frühen Mittelalter. W. EFFERT (ed), Monumenta Germaniae Historica, Constitutiones et acta publica imperatorum et regum. THOMAS EBENDORFER, Chronica regum Romanorum, ed. H. ZIMMERMANN. MARTIN THURNER (ed), Nicolaus Cusanus zwischen Deutschland und Italien. PEDRO ABELARDO, Diálogo entre un filósofo, un judío y un Cristiano, trad. SILVIA MAGNAVACCA. M. ÁLVAREZ GÓMEZ / J. MARÍA ANDRÉ, Coincidencia de opuestos y concordia. Los caminos del pensamiento en Nicolás de Cusa. J. IGNASI SARANYANA, La filosofía medieval. Desde sus orígenes patrísticos hasta la Escolástica barroca. TOMÁS DE AQUINO-PEDRO DE ALVERNIA, Comentario a la Política de Aristóteles, trad. A. MALLEA. G. FERNÁNDEZ DE OVIEDO, Claribalte, ed. M. J. RODILLA LEÓN. RICCARDO QUINTO, Scholastica. Storia di un concetto. LUIS ALBERTO DE BONI, De Abelardo a Lutero. Estudos sobre filosofia prática na Idade Media. O. B. Rader (ed), “Turbata per aequora mundi”

Improving the conservation of Mediterranean Chondrichthyans : the ELASMOMED DNA barcode reference library

Cartilaginous fish are particularly vulnerable to anthropogenic stressors and environmental change because of their K-selected reproductive strategy. Accurate data from scientific surveys and landings are essential to assess conservation status and to develop robust protection and management plans. Currently available data are often incomplete or incorrect as a result of inaccurate species identifications, due to a high level of morphological stasis, especially among closely related taxa. Moreover, several diagnostic characters clearly visible in adult specimens are less evident in juveniles. Here we present results generated by the ELASMOMED Consortium, a regional network aiming to sample and DNA-barcode the Mediterranean Chondrichthyans with the ultimate goal to provide a comprehensive DNA barcode reference library. This library will support and improve the molecular taxonomy of this group and the effectiveness of management and conservation measures. We successfully barcoded 882 individuals belonging to 42 species (17 sharks, 24 batoids and one chimaera), including four endemic and several threatened ones. Morphological misidentifications were found across most orders, further confirming the need for a comprehensive DNA barcoding library as a valuable tool for the reliable identification of specimens in support of taxonomist who are reviewing current identification keys. Despite low intraspecific variation among their barcode sequences and reduced samples size, five species showed preliminary evidence of phylogeographic structure. Overall, the ELASMOMED initiative further emphasizes the key role accurate DNA barcoding libraries play in establishing reliable diagnostic species specific features in otherwise taxonomically problematic groups for biodiversity management and conservation actions.peer-reviewe